← Ablatotech Vitals
Allergy EvidenceDigest

Advances in the Diagnosis and Management of Allergic Reactions to Biologic Therapies Targeting TSLP Pathways

Allergy · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Biologic therapies targeting thymic stromal lymphopoietin (TSLP) pathways represent a promising advance in managing type 2 inflammatory airway diseases such as asthma and allergic rhinitis. While these agents have demonstrated efficacy in reducing exacerbations and improving symptoms, allergic reactions to TSLP-targeted biologics remain an emerging clinical concern. Current evidence suggests that hypersensitivity reactions are infrequent but warrant careful diagnosis and management due to potential severity. Clinicians should be aware of the clinical presentation, diagnostic approaches, and management strategies for allergic reactions to these novel biologics as their use expands in allergy practice.

Clinical bottom line

Biologic therapies targeting thymic stromal lymphopoietin (TSLP) pathways represent a promising advance in managing type 2 inflammatory airway diseases such as asthma and allergic rhinitis. While these agents have demonstrated efficacy in reducing exacerbations and improving symptoms, allergic reactions to TSLP-targeted biologics remain an emerging clinical concern. Current evidence suggests that hypersensitivity reactions are infrequent but warrant careful diagnosis and management due to potential severity. Clinicians should be aware of the clinical presentation, diagnostic approaches, and management strategies for allergic reactions to these novel biologics as their use expands in allergy practice.

What the evidence shows

TSLP is an epithelial-cell–derived cytokine that plays a key role in initiating and amplifying type 2 inflammation by activating dendritic cells and promoting Th2 responses. Targeting TSLP pathways with monoclonal antibodies has emerged as a novel therapeutic strategy in asthma and allergic rhinitis, with agents such as tezepelumab demonstrating clinical benefit (Song et al., 2026; Yamani et al., 2024). These biologics reduce airway inflammation and exacerbation rates by interrupting upstream inflammatory signaling.

Regarding allergic reactions, the literature indicates that hypersensitivity events to TSLP-targeted therapies are reported but relatively rare. The clinical spectrum ranges from mild infusion-related reactions to anaphylaxis, though large-scale safety data remain limited due to the recent introduction of these agents (Song et al., 2026). Diagnostic evaluation typically involves clinical history, skin testing, and in some cases, graded drug challenges, although standardized protocols specific to TSLP biologics are not yet established.

Management of allergic reactions includes immediate discontinuation of the offending agent, administration of antihistamines, corticosteroids, and epinephrine for anaphylaxis, and consideration of desensitization protocols in select cases. Given the novelty of TSLP-targeted therapies, evidence-based guidelines for managing hypersensitivity reactions are extrapolated from experience with other biologics (Yamani et al., 2024).

Caveats and uncertainty

The evidence base for allergic reactions to TSLP-targeted biologics is still evolving. Most safety data derive from clinical trials with limited patient numbers and relatively short follow-up periods, which may underestimate rare or delayed hypersensitivity events (Song et al., 2026). Additionally, the immunologic mechanisms underlying these reactions remain incompletely understood, complicating risk stratification and prevention.

There is also a lack of consensus on diagnostic criteria and testing methods specific to TSLP biologics, which may lead to underdiagnosis or misclassification of allergic reactions. Furthermore, the potential cross-reactivity with other biologics targeting related pathways (e.g., IL-33, IL-4/IL-13) is not well characterized (Song et al., 2026).

Finally, patient populations in trials may not fully represent real-world diversity, including those with multiple atopic comorbidities or complex medication regimens, which could influence reaction risk and management outcomes.

How this may change practice

As TSLP-targeted biologics become more widely used in allergy and pulmonology, clinicians should incorporate vigilance for allergic reactions into routine monitoring. Early recognition and prompt management of hypersensitivity events can improve patient safety and treatment continuity.

Allergy specialists may need to develop or adopt standardized protocols for evaluating suspected allergic reactions to TSLP biologics, including skin testing and graded challenges adapted from other biologic agents. Multidisciplinary collaboration with pulmonologists and immunologists will be important for optimizing patient care.

Education of patients regarding potential allergic symptoms and when to seek urgent care is essential. In select cases, desensitization or switching to alternative biologics targeting different pathways may be considered.

Ongoing pharmacovigilance and real-world data collection are critical to refine risk profiles and management guidelines. Future research should focus on elucidating immunopathogenesis, identifying biomarkers predictive of hypersensitivity, and establishing evidence-based diagnostic and therapeutic algorithms.


References

  1. Song Guo-qiang, et al. Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD. Frontiers in Immunology 2026; DOI:10.3389/fimmu.2026.1772031
  2. Yamani Ibtihal, et al. Efficacy of Biologic Therapies in the Management of Allergic Rhinitis: A Systematic Review. Cureus 2024; DOI:10.7759/cureus.71408
  3. , et al. Current and Emerging Biologic Therapies for the Treatment of Asthma: A Focus on Targeting Thymic Stromal Lymphopoietin (TSLP). Medicon Medical Sciences 2025; DOI:10.55162/mcms.09.308

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team